Compare Natera Inc. Common Stock (NTRA) vs Vanguard S&P 500 Growth Index Fund ETF (VOOG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Vanguard S&P 500 Growth Index Fund ETF — how do they compare? Natera Inc. Common Stock trades at $393.27 (market cap $57.03B), while Vanguard S&P 500 Growth Index Fund ETF trades at $84.5 (market cap $27.10B). The key difference: Natera Inc. Common Stock is far larger — about 2.1× Vanguard S&P 500 Growth Index Fund ETF's market cap, and Vanguard S&P 500 Growth Index Fund ETF is more actively traded (775,650 versus 1,131,157). Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Vanguard S&P 500 Growth Index Fund ETF for 56 Days on average.
| NTRA | VOOG | |
|---|---|---|
Market Cap | $57.03B | $27.10B |
Volume | 1,131,157 | 775,650 |
Sector | Health | Broad Market / Factor |
52-Week High | $425.64 | $87.81 |
52-Week Low | $179.42 | $65.32 |
Typical Hold Time | 0 Days | 56 Days |
Enterprise Value | $56.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
VOOG trades at $86.9, down slightly by 0.02% on the day, with a bullish technical signal from moving averages and neutral oscillators. The ETF, tracking S&P 500 growth stocks, has seen strong institutional buying and positive media coverage highlighting its long-term growth potential and low expense ratio of 0.07%.
The outlook remains favorable for growth-oriented investors, supported by historical outperformance and sector concentration in technology. Key risks include market volatility and reliance on mega-cap tech stocks, but analyst sentiment and institutional inflows suggest continued confidence in its strategy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Vanguard S&P 500 Growth Index Fund ETF
VOOG is an index-based ETF that tracks the S&P 500 Growth Index, composed of the growth-oriented companies within the S&P 500. It selects constituents based on three key metrics—sales growth, the ratio of earnings change to price, and momentum—offering a highly liquid and low-cost way to capture the high-performing 'growth slice' of the broader U.S. large-cap market.
Read more on VOOG →
